Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 3
1985 2
1986 1
1987 20
1988 4
1989 2
1990 12
1991 7
1992 24
1993 4
1994 11
1995 7
1996 17
1997 12
1998 10
1999 21
2000 23
2001 40
2002 36
2003 30
2004 44
2005 50
2006 41
2007 58
2008 34
2009 21
2010 24
2011 28
2012 36
2013 40
2014 23
2015 24
2016 24
2017 16
2018 9
2019 11
2020 6
2021 7
2022 5
2023 7
2024 7
2025 7
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

739 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A; Carvedilol Or Metoprolol European Trial Investigators. Poole-Wilson PA, et al. Lancet. 2003 Jul 5;362(9377):7-13. doi: 10.1016/S0140-6736(03)13800-7. Lancet. 2003. PMID: 12853193 Clinical Trial.
The all-cause mortality was 34% (512 of 1511) for carvedilol and 40% (600 of 1518) for metoprolol (hazard ratio 0.83 [95% CI 0.74-0.93], p=0.0017). ...INTERPRETATION: Our results suggest that carvedilol extends survival compared with metoprolol....
The all-cause mortality was 34% (512 of 1511) for carvedilol and 40% (600 of 1518) for metoprolol (hazard ratio 0.83 [95% CI 0.74-0.9 …
Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Watanabe H, Ozasa N, Morimoto T, Shiomi H, Bingyuan B, Suwa S, Nakagawa Y, Izumi C, Kadota K, Ikeguchi S, Hibi K, Furukawa Y, Kaji S, Suzuki T, Akao M, Inada T, Hayashi Y, Nanasato M, Okutsu M, Kametani R, Sone T, Sugimura Y, Kawai K, Abe M, Kaneko H, Nakamura S, Kimura T; CAPITAL-RCT investigators. Watanabe H, et al. PLoS One. 2018 Aug 28;13(8):e0199347. doi: 10.1371/journal.pone.0199347. eCollection 2018. PLoS One. 2018. PMID: 30153268 Free PMC article. Clinical Trial.
Between August 2010 and May 2014, 801 patients were randomly assigned to the carvedilol group (N = 399) or the no beta-blocker group (N = 402) at 67 centers in Japan. ...TRIAL REGISTRATION: CAPITAL-RCT (Carvedilol Post-Intervention Long-Term Administration in Large- …
Between August 2010 and May 2014, 801 patients were randomly assigned to the carvedilol group (N = 399) or the no beta-blocker group …
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Dargie HJ. Dargie HJ. Lancet. 2001 May 5;357(9266):1385-90. doi: 10.1016/s0140-6736(00)04560-8. Lancet. 2001. PMID: 11356434 Clinical Trial.
FINDINGS: Although there was no difference between the carvedilol and placebo groups in the number of patients with the primary endpoint (340 [35%] vs 367 [37%], hazard ratio 0.92 [95% CI 0.80-1.07]), all-cause mortality alone was lower in the carvedilol group than …
FINDINGS: Although there was no difference between the carvedilol and placebo groups in the number of patients with the primary endpo …
Effect of carvedilol on survival in severe chronic heart failure.
Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Packer M, et al. N Engl J Med. 2001 May 31;344(22):1651-8. doi: 10.1056/NEJM200105313442201. N Engl J Med. 2001. PMID: 11386263 Free article. Clinical Trial.
RESULTS: There were 190 deaths in the placebo group and 130 deaths in the carvedilol group. This difference reflected a 35 percent decrease in the risk of death with carvedilol (95 percent confidence interval, 19 to 48 percent; P=0.00013, unadjusted; P=0.0014, adjus …
RESULTS: There were 190 deaths in the placebo group and 130 deaths in the carvedilol group. This difference reflected a 35 percent de …
Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to beta-blockers: A double-blind, placebo-controlled, randomized trial.
Alvarado-Tapias E, Brujats A, Puente A, Ardevol A, Rodriguez-Arias A, Fajardo J, Pavel O, Garcia-Guix M, Aracil C, Poca M, Cuyàs B, Cantó E, Montañés R, Garcia-Osuna A, Escorsell À, Torras X, Villanueva C. Alvarado-Tapias E, et al. Hepatology. 2025 Jul 1;82(1):140-154. doi: 10.1097/HEP.0000000000001148. Epub 2024 Nov 7. Hepatology. 2025. PMID: 39509369 Clinical Trial.
RESULTS: Of 184 eligible patients, 82 were randomized to carvedilol + simvastatin (N = 41) or carvedilol + placebo (N = 41). Baseline characteristics were similar. HVPG significantly decreased with both, carvedilol + simvastatin (18.6 4 to 15.7 4 mm Hg, p …
RESULTS: Of 184 eligible patients, 82 were randomized to carvedilol + simvastatin (N = 41) or carvedilol + placebo (N = 41). B …
Carvedilol.
[No authors listed] [No authors listed] Can Fam Physician. 1999 May;45:1199-202, 1205-9. Can Fam Physician. 1999. PMID: 10349064 Free PMC article. Clinical Trial.
Carvedilol is the first beta-blocker to obtain approval for treatment of heart failure. Improvement in hemodynamic parameters was initially documented in three methodologically sound studies involving 156 patients. ...When treatment is introduced very gradually, adverse ef …
Carvedilol is the first beta-blocker to obtain approval for treatment of heart failure. Improvement in hemodynamic parameters was ini …
Risk-guided cardioprotection with carvedilol in patients with breast cancer (CCT guide): a phase 1 randomized clinical trial.
Jung W, Hubbard RA, Smith AM, Ko K, Huang A, Wang J, Isaacs JM, Zhang L, Liu PP, Chen Z, Shah PD, Mintzer D, Bhattacharya S, Knollman HM, Clark AS, Koropeckyj-Cox D, Messinger M, Wilcox NS, Xia C, Narayan V, Upshaw JN, Armenian SH, Ky B. Jung W, et al. Breast Cancer Res Treat. 2025 Jun;211(2):293-305. doi: 10.1007/s10549-025-07636-3. Epub 2025 Apr 2. Breast Cancer Res Treat. 2025. PMID: 40172740 Free PMC article. Clinical Trial.
Elevated risk participants were randomized to receive open-label carvedilol or usual care for 12 months, beginning at cancer therapy initiation. Study visits occurred at baseline, 3, 6, 9, 12, and 24 months. ...Within the elevated risk group, 13 were randomized to carve …
Elevated risk participants were randomized to receive open-label carvedilol or usual care for 12 months, beginning at cancer therapy …
Carvedilol Plus NUC for Patients With HBV-Compensated Cirrhosis Under Virological Suppression: A Randomized Open-Label Trial.
Wang B, Zhou J, Wu X, Sun Y, Li L, Li P, Li M, Jiang W, Xu M, Feng B, Xu X, Cheng J, Xie W, Han T, Wang X, Li H, Piao H, Zhao X, Chen S, Meng T, Guan Q, Meng F, Kong Y, Ou X, Jia J, You H. Wang B, et al. Am J Gastroenterol. 2024 Apr 1;119(4):700-711. doi: 10.14309/ajg.0000000000002569. Epub 2023 Nov 6. Am J Gastroenterol. 2024. PMID: 37929952 Clinical Trial.
RESULTS: A total of 238 patients (small EV, 77.3%) were randomized into 119 NUC and 119 carvedilol plus NUC (carvedilol [CARV] combination group). Among them, 205 patients (86.1%) completed paired endoscopies. ...However, the carvedilol-added approach might o …
RESULTS: A total of 238 patients (small EV, 77.3%) were randomized into 119 NUC and 119 carvedilol plus NUC (carvedilol [CARV] …
Clinical Characteristics and Outcome of Immediate-Release Versus SLOW-Release Carvedilol in Heart Failure Patient (SLOW-HF): a Prospective Randomized, Open-Label, Multicenter Study.
Park CS, Park JJ, Lee HY, Kang SM, Yoo BS, Jeon ES, Hong SK, Shin JH, Kim MA, Park DG, Kim EJ, Hong SJ, Kim SY, Kim JJ, Choi DJ. Park CS, et al. Cardiovasc Drugs Ther. 2023 Jun;37(3):529-537. doi: 10.1007/s10557-021-07238-3. Epub 2022 Jan 23. Cardiovasc Drugs Ther. 2023. PMID: 35066737 Clinical Trial.
We investigated whether slow-release carvedilol (carvedilol-SR) is non-inferior to standard immediate-release carvedilol (carvedilol-IR) in terms of clinical efficacy in patients with HFrEF. ...For safety outcomes, the occurrence of adverse reactions d …
We investigated whether slow-release carvedilol (carvedilol-SR) is non-inferior to standard immediate-release carvedilol …
Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial.
Roberts MA, Darssan D, Badve SV, Carroll RP, Fahim MA, Haluska BA, Hawley CM, Isbel NM, Marshall MR, Pascoe EM, Pedagogos E, Pilmore HL, Snelling P, Stanton T, Tan KS, Tonkin AM, Vergara LA, Ierino FL. Roberts MA, et al. Kidney Blood Press Res. 2017;42(6):1033-1044. doi: 10.1159/000485589. Epub 2017 Dec 4. Kidney Blood Press Res. 2017. PMID: 29197871 Free article. Clinical Trial.
Our aim was to report the effect of the beta-blocker carvedilol on cardiac biomarkers in adult dialysis patients. METHODS: The Beta-Blocker to Lower Cardiovascular Dialysis Events Feasibility Study was a randomized controlled trial comparing carvedilol to placebo. . …
Our aim was to report the effect of the beta-blocker carvedilol on cardiac biomarkers in adult dialysis patients. METHODS: The Beta-B …
739 results